MedTrace Logo

The Efficacy of White Kidney Bean on Oral Glucose Tolerance Test

NCT05756712 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2023-04-04

No results posted yet for this study

Summary

The goal of this randomized, double-blind, cross-over inverventional study is to evaluate the efficacy of white kidney bean on OGTT (oral glucose tolerance test). About 34 eligible participants will be randomized in two groups of the same size to take the assigned interventions at one study site in Shanghai, two visits will be required. The first group of participants will take Wonderlab product first and then placebo product after 72 hours of washout period, while the other group of of participants will take placebo product first and then Wonderlab product after 72 hours of washout period. For each visit, the finger blood will be sampled and the relevent data such as blood glucose will be captured based on OGTT procedures, and recorded into clinical data management system for statistical analysis.

Researchers will compare the two groups to see if there is significant change of blood glucose by using products containing ingredient of white kidney beans.

Conditions

Interventions

DIETARY_SUPPLEMENT

Phase 1 Wonderlab Product

Chew two tablets of Wonderlab Product for phase 1 (day 1)

DIETARY_SUPPLEMENT

Phase 1 Placebo

Washout 72 hours and chew two tablets of placebo for phase 2 (day 4).

DIETARY_SUPPLEMENT

Phase 2 Placebo

Chew two tablets of placebo for phase 1 (day 1)

DIETARY_SUPPLEMENT

Phase 2 Wonderlab Product

Washout 72 hours and chew two tablets of Wonderlab Product for phase 2 (day 4).

Sponsors & Collaborators

  • Shenzhen Precision Health Food Technology Co. Ltd.,

    lead OTHER_GOV

Principal Investigators

  • Charlie Zhang, MD · SPRIM Medical

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
25 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-03-06
Primary Completion
2023-03-15
Completion
2023-03-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05756712 on ClinicalTrials.gov